Understanding the Trump Administration’s Marijuana Policy Shift and What It Means for Wisconsin
On Thursday, Acting U.S. Attorney General Todd Blanche issued a directive that reclassifies certain marijuana‑containing products from Schedule I to Schedule III under the Controlled Substances Act. The move does not legalize marijuana federally, but it signals a changing federal stance that advocates hope will influence state‑level reforms, including in Wisconsin.
What the Federal Order Actually Does
The order applies specifically to:
- Food and Drug Administration‑approved medications that contain cannabis or its derivatives.
- State‑licensed medical marijuana programs.
By placing these products in Schedule III, the government acknowledges a lower potential for abuse compared with Schedule I substances like heroin. According to the Department of Justice, Schedule III drugs are considered to have “moderate to low potential for physical and psychological dependence.”
Blanche emphasized that the change “allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information.”
Why Wisconsin Remains Largely Unaffected—For Now
Wisconsin is one of only a handful of states that has not enacted a comprehensive medical marijuana law. Consequently, the rescheduling of FDA‑approved cannabis products does not automatically change state statutes. Possession, cultivation, and distribution of marijuana for any purpose remain illegal under Wisconsin law, except for the limited hemp‑derived products discussed below.
David Gwidt, a spokesman for the American Civil Liberties Union of Wisconsin, noted in a statement that “the reclassification underscores the growing acceptance of medical cannabis and cannabis use in general,” urging state leaders to consider legalization reflecting the preferences of the majority of Wisconsin residents.
Activist Perspectives
Indigenous Cannabis Industry Association president Rob Pero, who also co‑founded the Wisconsin Wellness Coalition, told reporters that the federal shift could ease legislative hesitancy: “This really relieves a lot of pressure on our Legislature, even those that were very conservative in regards to their opinion of this plant. This will swing and build momentum for Wisconsin.”
Jay Selthofner, founder of the Wisconsin Cannabis Activist Network, described the order as “a step in the right direction,” while cautioning that “rescheduling is not legalization.” He argued for a broader federal withdrawal from cannabis prohibition.
What About the Weed Shops Already Operating in Wisconsin?
Despite state prohibitions, several storefronts sell CBD and THC‑infused products. These businesses rely on a loophole created by the 2018 Farm Bill, which permits the cultivation and sale of hemp containing no more than 0.3 % delta‑9‑THC on a dry‑weight basis.
However, a forthcoming federal rule—set to take effect this fall—will revise the definition of hemp, effectively closing that loophole. Once the rule is in place, many of the current products may no longer be legally marketable without state authorization.
Federal Efforts to Fully Reclassify Marijuana
Separate from the medical‑marijuana directive, the Trump administration has accelerated a review that could eventually move all cannabis—including recreational use—from Schedule I to Schedule III. An administrative hearing on this broader rescheduling is scheduled for June 29, 2025.
The review originated under the Biden administration, but Selthofner noted that activists are “very happy to see a new attorney general responding very positively to Trump’s request to basically expedite this particular process.”
Looking Ahead: Potential Pathways for Wisconsin
Experts suggest that the combination of federal rescheduling, growing public support, and successful medical‑marijuana programs in neighboring states could create a favorable environment for reform in Wisconsin. A 2023 Marquette University Law School poll found that 61 % of Wisconsin residents favor legalizing marijuana for medical use, while 48 % support recreational legalization.
If state lawmakers respond to these signals, Wisconsin could join the growing list of states that have established regulated medical cannabis programs, potentially improving patient access, generating tax revenue, and reducing criminal‑justice burdens linked to low‑level marijuana offenses.
Conclusion
The Trump administration’s recent order does not overturn federal prohibition, but it represents a measurable shift in how the government classifies certain cannabis products. For Wisconsin, where marijuana remains illegal under state law, the change offers both a symbolic endorsement of medical cannabis’s legitimacy and a practical impetus for activists and policymakers to revisit the state’s stance. Continued monitoring of federal developments, coupled with robust public opinion data, will be essential as Wisconsin navigates its path forward.
Source: Here
